Literature DB >> 8005388

T cell anergy.

J M LaSalle1, D A Hafler.   

Abstract

T cell clonal anergy is a proposed mechanism of immunologic self tolerance in which T cells become functionally inactivated after previous stimulation. MHC class II-restricted antigen presentation by different cell types has been speculated to have a role in determining activation vs. anergy in responding T cells. Human T cells express MHC class II after activation and have been shown to present high concentrations of degraded peptide antigen to autologous T cells resulting in clonal anergy. In contrast to low antigen dose T cell clonal anergy, which occurs in the absence of costimulation, T cell anergy induced by human T cell presentation of antigen results in both primary proliferation and secondary unresponsiveness to high-dose antigenic stimulation. Although clonal anergy was previously thought to prevent autoreactive T cells from ever responding to self antigen presented without costimulation, we postulate that T cell presentation of antigen represents a "fail-safe" mechanism of immunologic self tolerance that would anergize clonally expanded autoreactive T cells when they are surrounded by a high extracellular concentration of degraded self antigen.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8005388     DOI: 10.1096/fasebj.8.9.8005388

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  14 in total

Review 1.  T cell-mediated antigen presentation: a potential mechanism of infectious tolerance.

Authors:  M D Mannie
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 2.  Involvement of CD80 in the generation of CD4+ cytotoxic T cells.

Authors:  D Mauri; W J Pichler
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

Review 3.  Immunologic tolerance in renal transplantation.

Authors:  D A Shoskes
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

4.  CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites.

Authors:  V S Shapiro; K E Truitt; J B Imboden; A Weiss
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

5.  Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients.

Authors:  Chiara Agrati; Cristiana Gioia; Concetta Castilletti; Daniele Lapa; Giulia Berno; Vincenzo Puro; Fabrizio Carletti; Eleonora Cimini; Carla Nisii; Flora Castellino; Federico Martini; Maria R Capobianchi
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-08       Impact factor: 2.205

6.  Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?

Authors:  Pawel Kalinski; Howard Edington; Herbert J Zeh; Hideho Okada; Lisa H Butterfield; John M Kirkwood; David L Bartlett
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

7.  Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergy.

Authors:  M Ali; F Ponchel; K E Wilson; M J Francis; X Wu; A Verhoef; A W Boylston; D J Veale; P Emery; A F Markham; J R Lamb; J D Isaacs
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

Review 8.  New approaches to the development of adenoviral dendritic cell vaccines in melanoma.

Authors:  Lisa H Butterfield; Lazar Vujanovic
Journal:  Curr Opin Investig Drugs       Date:  2010-12

Review 9.  Immunological self/nonself discrimination: integration of self vs nonself during cognate T cell interactions with antigen-presenting cells.

Authors:  M D Mannie
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

10.  Soluble Antigen Arrays Efficiently Deliver Peptides and Arrest Spontaneous Autoimmune Diabetes.

Authors:  Rebuma Firdessa-Fite; Stephanie N Johnson; Martin A Leon; Mohsen Khosravi-Maharlooei; Rocky L Baker; Joshua O Sestak; Cory Berkland; Remi J Creusot
Journal:  Diabetes       Date:  2021-01-19       Impact factor: 9.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.